Protocol Ledger

NCT05860465 · Phase II/III · RECRUITING

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Interventional Phase II/III clinical trial protocol NCT05860465 sponsored by Shanghai Pharmaceuticals Holding Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-08 Enrollment: 254 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05860465
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)254 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05860465
Protocol FieldVerified Registry Value
NCT IdentifierNCT05860465
Consolidated Lead SponsorShanghai Pharmaceuticals Holding Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment254 participants (ESTIMATED)
Registered Start Date2023-09-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI